MX2022016066A - Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. - Google Patents

Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.

Info

Publication number
MX2022016066A
MX2022016066A MX2022016066A MX2022016066A MX2022016066A MX 2022016066 A MX2022016066 A MX 2022016066A MX 2022016066 A MX2022016066 A MX 2022016066A MX 2022016066 A MX2022016066 A MX 2022016066A MX 2022016066 A MX2022016066 A MX 2022016066A
Authority
MX
Mexico
Prior art keywords
viral
treatment
infection
inhibitor
bacterial infections
Prior art date
Application number
MX2022016066A
Other languages
English (en)
Inventor
Stephan Ludwig
Oliver Planz
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Publication of MX2022016066A publication Critical patent/MX2022016066A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a PD-0184264 para uso en un método para la profilaxis y/o tratamiento de una co-infección que comprende una infección bacteriana y una infección por virus de influenza o solo una infección viral o bacteriana. También se proporcionan composiciones que comprenden estos inhibidores para uso en la profilaxis y/o tratamiento de una co-infección que comprende una infección bacteriana y una infección por virus de influenza o solo una infección bacteriana o viral.
MX2022016066A 2017-10-17 2020-07-13 Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. MX2022016066A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU100487 2017-10-17

Publications (1)

Publication Number Publication Date
MX2022016066A true MX2022016066A (es) 2023-02-02

Family

ID=60484427

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003473A MX2020003473A (es) 2017-10-17 2018-10-17 Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
MX2022016066A MX2022016066A (es) 2017-10-17 2020-07-13 Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020003473A MX2020003473A (es) 2017-10-17 2018-10-17 Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.

Country Status (21)

Country Link
US (1) US11903917B2 (es)
EP (2) EP3697405B1 (es)
JP (2) JP7227967B2 (es)
KR (1) KR20200072499A (es)
CN (2) CN118141795A (es)
AU (1) AU2018351475A1 (es)
BR (1) BR112020007442A2 (es)
CA (1) CA3078424A1 (es)
CY (1) CY1124507T1 (es)
DK (1) DK3697405T3 (es)
EA (1) EA202090693A1 (es)
ES (1) ES2883639T3 (es)
HR (1) HRP20211252T1 (es)
HU (1) HUE055738T2 (es)
LT (1) LT3697405T (es)
MX (2) MX2020003473A (es)
PL (1) PL3697405T3 (es)
PT (1) PT3697405T (es)
SI (1) SI3697405T1 (es)
WO (1) WO2019076947A1 (es)
ZA (1) ZA202002069B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114667138A (zh) * 2019-08-27 2022-06-24 归属疗法有限公司 Mek抑制剂与帽状结构依赖型核酸内切酶抑制剂的组合
EP4041212A1 (en) * 2019-10-08 2022-08-17 Atriva Therapeutics GmbH Mek inhibitors for the treatment of hantavirus infections
CN112957361B (zh) * 2021-03-24 2022-07-29 中国科学院武汉病毒研究所 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
JP2002534381A (ja) * 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた抗ウィルス法
TR200200082T2 (tr) * 1999-07-16 2002-04-22 Warner-Lambert Company MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
CA2473545A1 (en) 2002-01-23 2003-07-31 Warner-Lambert Company Llc N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
JP2007055983A (ja) * 2005-08-26 2007-03-08 Tokyo Univ Of Science 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤
ES2575995T3 (es) * 2010-08-05 2016-07-04 Case Western Reserve University Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
EA028605B1 (ru) * 2012-10-08 2017-12-29 Атрива Терапьютикс Гмбх Комбинация озельтамивира и ингибитора mek для лечения вирусных заболеваний
JP6818676B2 (ja) * 2014-05-16 2021-01-20 アトリバ セラピューティクス ゲーエムベーハー インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略
EP4041212A1 (en) 2019-10-08 2022-08-17 Atriva Therapeutics GmbH Mek inhibitors for the treatment of hantavirus infections
EP3912623A1 (en) 2020-05-20 2021-11-24 Atriva Therapeutics GmbH Mek-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm

Also Published As

Publication number Publication date
HUE055738T2 (hu) 2021-12-28
JP2020537659A (ja) 2020-12-24
CY1124507T1 (el) 2022-07-22
ZA202002069B (en) 2021-10-27
EA202090693A1 (ru) 2020-10-19
US20200289445A1 (en) 2020-09-17
JP2023058631A (ja) 2023-04-25
JP7227967B2 (ja) 2023-02-22
MX2020003473A (es) 2020-10-01
CN118141795A (zh) 2024-06-07
EP3697405A1 (en) 2020-08-26
AU2018351475A1 (en) 2020-04-30
WO2019076947A1 (en) 2019-04-25
ES2883639T3 (es) 2021-12-09
CA3078424A1 (en) 2019-04-25
PL3697405T3 (pl) 2021-12-13
KR20200072499A (ko) 2020-06-22
PT3697405T (pt) 2021-08-27
DK3697405T3 (da) 2021-08-23
US11903917B2 (en) 2024-02-20
LT3697405T (lt) 2021-10-25
SI3697405T1 (sl) 2021-11-30
BR112020007442A2 (pt) 2020-10-27
CN111479566B (zh) 2024-05-07
EP3973960A1 (en) 2022-03-30
EP3697405B1 (en) 2021-07-14
CN111479566A (zh) 2020-07-31
HRP20211252T1 (hr) 2021-11-12

Similar Documents

Publication Publication Date Title
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
PH12017500207B1 (en) Indoles for use in influenza virus infection
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
AU2016361583A8 (en) Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
IL281277A (en) Preparations and methods for treating viral infections
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
EA201692303A1 (ru) Новая противоинфекционная стратегия против коинфекций, вызванных вирусом гриппа и s.aureus
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
PH12016502559A1 (en) Isoindoline derivatives for use in the treatment of a viral infection
IL290792A (en) Preparations and methods for treating viral infections
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
ZA202002093B (en) Antibacterial compounds
ZA202202370B (en) Compositions and methods for treating viral infections
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
WO2018237010A3 (en) VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
MX2017006138A (es) Composiciones farmaceuticas de accion prolongada para hepatitis c.
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
MX2018000384A (es) Composiciones para el tratamiento contra infecciones.
MX2021005234A (es) Compuestos para el tratamiento de la infeccion por arenavirus.